Chemistry: molecular biology and microbiology – Virus or bacteriophage – except for viral vector or...
Reexamination Certificate
2007-06-26
2007-06-26
Campell, Bruce R. (Department: 1648)
Chemistry: molecular biology and microbiology
Virus or bacteriophage, except for viral vector or...
C435S326000, C435S007240
Reexamination Certificate
active
10436388
ABSTRACT:
Cell preparations comprising a plurality of apoptotic EBV-transformed B lymphocytes and methods of producing cell preparations comprising a plurality of apoptotic EBV-transformed B lymphocytes. The methods comprise transforming B lymphocytes with EBV, incubating the transformed B lymphocytes with a flavin N-oxide photosensitizer, adding a non-toxic antioxidant, and exposing the lymphocytes to an activator, such as photoradiation of an appropriate wavelength to activate the photosensitizer. Also provided are methods of using the apoptotic EBV-transformed B lymphocyte cell preparations to elicit production of EBV-specific T cells in human patients. Finally, methods of treating organ transplant patients, specifically children, comprising administering an effective amount of the apoptotic EBV-transformed B-lymphocyte cell preparation to the patient prior to transplantation are provided.
REFERENCES:
patent: 5945420 (1999-08-01), Araki et al.
patent: 6001882 (1999-12-01), Fox et al.
patent: 6177441 (2001-01-01), Cook et al.
patent: 6268120 (2001-07-01), Platz et al.
patent: 6503699 (2003-01-01), Wollowitz et al.
patent: 6514987 (2003-02-01), Cook et al.
patent: 6933285 (2005-08-01), Platz et al.
patent: 2002/0028432 (2002-03-01), Cook et al.
patent: 2002/0182581 (2002-12-01), Cook et al.
Fersi, Hannan, M.S., “Binding Affinities of Sensitizers of Pathogen Eradication and Photochemical Behavior of Riboflavin and Riboflavin-N-Oxide,” A Thesis, 2002, The Ohio State University.
Brown, J.M., “SR 4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours,” Br. J. Cancer 67, pp. 1163-1170, 1993, Macmillan Press Ltd.
Daniels, J. Scott et al., “DNA Cleavage by the Antitumor Agent 3-Amino-1,2,4-benzotriazine 1,4-Dioxide (SR4233): Evidence for Involvement of Hydroxyl Radical,” J. Am. Chem. Soc., 118, pp. 3380-3385, 1996, American Chemical Society.
Brown, J.M., “Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies,” Molecular Medicine Today, vol. 6, pp. 157-162, London, UK, 2000.
Kelson, Andrew B. et al., “1,2,4-Benzotriazine 1,4-dioxides. An important class of hypoxic cytotoxins with antitumor activity,” Anti-Cancer Drug Design, 13, pp. 575-592, Oxford Univ. Press, 1998.
Brown, J.M., “The Hypoxic Cell: A Target for Selective Cancer Therapy—Eighteenth Bruce F. Cain Memorial Award Lecture,” Cancer Research, 59, pp. 5863-5870, Stanford, CA, Dec. 1, 1999.
Brown, J.M. et al., “Tirapazamine: laboratory data relevant to clinical activity,” Anti-Cancer Drug Design, 13, pp. 529-539, Oxford Univ. Press, 1998.
Evans, James W. et al., “Tirapazamine is Metabolized to Its DNA-damaging Radical byIntranuclear Enzymes,” Cancer Research, 58, pp. 2098-2101, Stanford, CA, May 15, 1998.
Daniels, J.S. et al., “Photochemical DNA Cleavage by the Antitumor Agent 3-Amino-1,2,4-Benzotriazine 1,4-Dioxide (Tirapazamine, WIN 59075, SR4233),” The Journal of Organic Chemistry, vol. 63, No. 26, pp. 10027-10030, American Chemical Society, 1998.
Patterson, Laurence H. et al., “Electron Paramagnetic Resonance Spectrometry Evidence for Bioreduction of Tirapazamine to Oxidising Free Radicals Under Anaerobic Conditions,” Biochemical Pharmacology, Vo. 60, pp. 1933-1935, Elsevier Science Inc., 2000.
Durandy, A. et al., “Sensitivity of EB virus-induced B cell tumor to apoptosis mediated by anti-CD95/Apo-1 fas antibody,” Eur J Immunol, 1997, vol. 27, pp. 538-543.
Buckley, CD, et al. “RGD peptides induce apoptosis by direct caspase-3 activation”, Nature, vol. 397, Feb. 11, 1999, pp. 534-538.
Cahir-McFarland, ED et al “NF-kB inihibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells” PNAS, May 23, 2000 vol. 97, No. 11, 6055-6060.
Denny, WA, “The role of hypoxia-activated prodrugs in cancer therapy”, Lancelot Oncol. 2000, 1, pp. 25-29.
Kuratomi et al. “Studies on the interactions between DNA and Vlavins”, Biocim. Biophys. Acta. 1977, 476, 207-217.
Yoneda, F. et al. “Syntheses of Isoalloxazines and Isoalloxazine 5-Oxides. A New Synthesis of Riboflavin”, Jour. Am. Chemical Society, 98:3, Feb. 4, 1976, pp. 830-835.
International Search Report from PCT/US03/14684, Nov. 20, 2003.
Calfee Halter & Griswold LLP
Campell Bruce R.
Hurt Sharon
The Ohio State University Research Foundation
LandOfFree
Apoptotic EBV-transformed lymphocytes, a therapeutic agent... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Apoptotic EBV-transformed lymphocytes, a therapeutic agent..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Apoptotic EBV-transformed lymphocytes, a therapeutic agent... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3880549